Broth microdilution MICs were determined for 258 clinical isolates of Mycobacterium fortuitum (3 biovariants) and M. chelonae (2 subspecies) with amikacin, tobramycin, cefoxitin, doxycycline, erythromycin, and sulfamethoxazole-trimethoprim and with several new jI-lactams and aminoglycosides and ciprofloxacin. Variations in susceptibility by and within species subgroups confirm the need for susceptibility testing against clinically important strains.
Broth microdilution MICs were determined for 258 clinical isolates of Mycobacterium fortuitum (3 biovariants) and M. chelonae (2 subspecies) with amikacin, tobramycin, cefoxitin, doxycycline, erythromycin, and sulfamethoxazole-trimethoprim and with several new jI-lactams and aminoglycosides and ciprofloxacin. Variations in susceptibility by and within species subgroups confirm the need for susceptibility testing against clinically important strains.
The role of the rapidly growing mycobacteria Mycobacterium fortuitum and M. chelonae (formerly M. chelonei) as agents of human disease has been clearly established (22) . Except for the aminoglycosides, these organisms are resistant to the antituberculosis agents, and testing against these drugs is no longer indicated (19) . However, they are susceptible to some drugs not routinely tested in laboratories specializing in mycobacteriology; these agents have been shown to be effective in the treatment of human disease (8, 9, 19, 21a) . Because the susceptibilities of M. fortuitum and M. chelonae to these agents varies, testing clinically important strains as an aid in determining a therapeutic regimen is important. Although the need to identify organisms of the M. fortuitum complex to subspecies and even species level remains controversial (11, 17) , previous studies have suggested that patterns of susceptibility may relate in part to differences between species, subspecies, and biovariants (17, 19, 20, 21, 23, 24) .
Between 1978 and 1982, more than 250 strains of rapidly growing mycobacteria were received in our laboratories for identification and susceptibility testing. In this report, we present the antimicrobial susceptibilities of organisms that were identified to the subspecies or subgroup level as determined by a broth microdilution method. Our results provide susceptibility data on a large number of organisms and confirm the need to determine the susceptibilities of M. fortuitum and M. chelonae. In addition, the results show that each species subgroup has a fairly typical pattern of susceptibility.
MATERIALS AND METHODS Ot-ganisms. Isolates were submitted to our laboratories for either identification or antimicrobial susceptibility determination, or both. Organisms were identified by standard methods (17) , except that the unnamed third biovariant of M. fortuitum was expanded to a complex which includes isolates positive for two or more carbohydrates (mannitol, inositol, or citrate). The strains and number included were M. fortuitum biovariant fortuitum, 98; M. fortuitum biovariant peregrinum, 8; M. fortuitum third biovariant complex, 19; M. chelonae subsp. abscessus, 99; and M. chelonae subsp. chelonae, 34. A small number of these strains were included in our previous study (19) . Isolates of the M. chelonae-like * Corresponding author. group were not included in this report because results with most of these strains were reported earlier (9) . Aspects of clinical disease and results of therapy for many of these isolates have been reported (8, 9, 21a, 22) .
The organisms were stored on Lowenstein-Jensen slants before testing and then were subcultured onto Trypticase soy sheep blood agar plates (BBL Microbiology Systems, Cockeysville, Md.) with a sterile cotton swab and incubated at 35°C in ambient air for 2 to 4 days. The inoculum for the susceptibility tests was prepared by using a sterile swab to transfer 3 to 5 colonies to 5-ml tubes of Mueller-Hinton broth (BBL or Difco Laboratories, Detroit, Mich.) supplemented with 0.02% Tween 80. The tubes were incubated at 35°C for 1 to 3 days until the turbidity of the culture equaled a 0.5 McFarland standard (14) . To avoid clumpy growth that was difficult to suspend, the inoculum broths were used as soon as the correct turbidity was reached.
Antimicrobial agents. The agents included in this report are the ones previously shown to be the most active against this group of organisms; several others were included because they were new agents that had not been reported previously (19) . Drugs were received from the manufacturer as powders suitable for susceptibility testing. The agents previously shown to be active on some strains were cefoxitin, amikacin, tobramycin, doxycycline, erythromycin, and sulfamethoxazole (SMX). (For some of the strains, SMX was tested in combination with trimethoprim, but since these organisms are resistant to trimethoprim [19, 21, 23] , any activity was assumed to be due to SMX, and the results are presented for that part of the combination only.) The newer agents tested included piperacillin, mezlocillin, azlocillin, cefotetan (a cephamycin), ceftriaxone, imipenem, aztreonam, amoxicillin-clavulanic acid (2:1), netilmicin, fortimicin, and ciprofloxacin. These newer agents were tested against a smaller number of strains than were the preceding agents.
Broth microdilution. Microdilution plates were prepared by using the MIC 2000 (Dynatech Laboratories, Inc., Alexandria, Va.) or the Quick Spense (Bellco Glass, Inc., Vineland, N.J.) systems. The antimicrobial agents were added to cation-supplemented Mueller-Hinton broth (not containing Tween 80), and then 0.1 ml was dispensed into the wells of microdilution plates (14) . The plates were sealed in plastic bags, stored at -70°C, and removed and thawed as needed.
Initially, the plates were inoculated with either the MIC 2000 mechanical inoculator or disposable inoculators, diluting so as to obtain a final inoculum of between 104 and 105 CFU/ml. Later it was decided to use only disposable inoculators to minimize aerosolization. The plates were sealed in plastic bags and incubated in room air at 35°C for 3 days.
Except for SMX, the MIC was read as the least concentration of drug that inhibited all visible growth. The MIC for SMX was the concentration that inhibited 80% of the growth compared with the growth control containing no drug. Susceptible and resistant breakpoints used (Table 1) were those recommended by the National Committee for Clinical Laboratory Standards (14) , except for resistance to cefoxitin, for which we used one dilution higher (>32 [LgIml), and resistance to SMX (>64 ,ug/ml), for which no level for nonurinary pathogens is given.
RESULTS
MICs are presented as cumulative percentages for six drugs by subgroups ( Table 2 ). Presenting the data in this manner makes it easier to show the differences between subgroups and is feasible because so few agents can be used to treat infections caused by these organisms.
Aminoglycosides. Amikacin has by far the greatest activity of all the agents tested against all five subgroups, but it is most active against the M. fortuitum biovariants. Tobramycin has good activity only against M. fortuitum biovariant peregrinum and M. chelonae subsp. chelonae. Because amikacin is used more often, kanamycin was not included in this study, although in a previous study it had slightly greater activity against M. chelonae isolates than did amikacin (19) .
Cefoxitin. At the moderately susceptible breakpoint of -32 ,ug/ml, cefoxitin was active against some strains of all subgroups tested except for M. chelonae subsp. chelonae. It was most active against M. fortuitum biovariant fortuitum and M. fortuitum biovariant peregrinum.
Doxycycline. As for most bacterial species, susceptibility to tetracycline is variable, being essentially bimodal. As shown previously (19) , however, when tetracyclines are active, doxycycline or minocycline are two-to eightfold more active than tetracycline. The last two analogs have comparable activity, and we tested doxycycline. M. chelonae subsp. abscessus was the most resistant to doxycycline of the five subgroups tested, with 96% of the isolates having MICs of >16 ,ug/ml. The most susceptible group was the M. fortuitum biovariant fortuitum, with 40% of the strains having MICs of '1 jig/ml.
Erythromycin. In general, all M. fortuitum biovariants should be considered resistant to erythromycin, although several strains of M. fortuitum biovariant peregrinum had (Table 3) .
Control strains. Control strains used were those recommended by the National Committee for Clinical Laboratory Standards for dilution testing (14) and were read after incubation for 24 h. Results were within the ranges published (14) . A control strain of M. fortuitum was also tested sporadically. The results for this strain are given in Table 4 . This is the de Costa Cruz strain (formerly TMCC 1529) which is the type strain of M. fortuitum. It is available from the American Type Culture Collectioh, Rockville, Md., as ATCC 6841.
DISCUSSION
Before 1978 the methods for testing the susceptibility of rapidly growing mycobacteria to antimicrobial agents involved variations of techniques that were more commonly used to test M. tuberculosis and the other slowly growing mycobacterial species. Some early published mhethods did use more standard bacterial techniques but used media that were considered best for the growth of mycobacteria (1, 10, 12, 15, 16) . Since 1978, however, more investigators have begun testing these species with standard methods recommended for testing other rapidly growing bacteria, e.g., Enterobacteriaceae and staphylococci (2) (3) (4) (5) (6) (7) (20) (21) (22) (23) (24) . We have previously shown that agar and broth microdilution methods work well when applied to M. fortuitum and M. chelonae (19) and that antimicrobial agents other than antituberculosis agents should be tested. However, we do prefer the broth test because M. chelonae grows better in broth than on agar, especially if no supplements such as oleic acid-albumin-glucose (dextrose)-catalase are added (OADC) (18, 19) .
We have encountered some minor potential or unresolved problems with this system for SMX, erythrornycin, and vancomycin. Sulfonamide susceptibility is very inoculum dependent, and false resistance to SMX among M. fortuitum can occur if too much inoculum is used. As has been noted previously (19) , erythromycin tends to produce a trailing endpoint with some strains of M. chelonae. In the strains which showed marked inhibition of growth compared with the control but had a very small amount of growth in a number of wells above this inhibition, it is not known if this growth has any importance clinically or if it should be ignored as is done with sulfonamides. With M. chlenoae subsp. chelonae, for example, essentially all strains may well be susceptible or moderately susceptible if this trailing endpoint were known to be unimportant. Vancomycin has been shown to have activity against M. fortuitum when tested in agar (13, 19) , but most isolates appear resistant when tested in broth (19) . These problems with erythromy- or not at all at 35°C and require incubation at lower temperatures of 28 to 29°C. Some members of this subspecies still grow poorly even at these temperatures, and incubation of the microdilution plates for an additional 24 to 48 h may be required to produce good growth. The M. fortuitum biovariants all grow much more rapidly and may produce adequate enough growth to be read at 48 h. We chose a 72 h period, because the species is often unknown at that time and almost all strains of both species can be read after this incubation time. Early readings may be possible with M. fortuitum, and MICs did not appear to change substantially over the next 24 h (J. M. Swenson, unpublished data).
No single agent was active against all the isolates of rapidly growing mycobacteria that we tested. Because susceptibility varies by species and in some cases by subspecies or biovariant and because therapy is limited to only a few agents, we suggest determining susceptibilities to amikacin, tobramycin, cefoxitin, erythromycin, doxycycline, and SMX with the strains of M. fortuitum and M. chelonae that have been shown to cause significant clinical infections. Most of the newer drugs that we tested had little activity against these isolates except for imipenem, ciprofloxacin, and, for some, amoxicillin-clavulanic acid. It is not known if the last three agents have any role in the therapy of infections caused by these bacteria, because there is little clinical data on them. However, because so few agents have any activity against these isolates, it may be useful to test them since amoxicillin-clavulanic acid has already been approved by the FDA and imipenem may be approved soon.
With a slightly modified standard broth microdilution ,g/ml (with trimethoprim included), levels too low (especially for cefoxitin) to detect susceptibility for many isolates. None of the systems include doxycycline. Tetracycline could be substituted for doxycycline, but the MICs will be two-to eightfold higher. Thus, at present, the use of a slightly modified standard broth microdilution method with one of the commercial systems may require adding more concentrations and drugs. For laboratories that handle small numbers of isolates, referral to a larger reference laboratory or determination of susceptibility by another method such as agar disk elution (18) may be more practical. In summary, the five subgroups of M. fortuitum and M. chelonae vary in their susceptibility to antimicrobial agents useful for therapy of these rapidly growing mycobacteria. Susceptibility tests should be performed to aid in determining appropriate therapeutic regimens; we recommend the broth microdilution method.
